Pimagedine inhibitor of the formation of advanced glycosylation end products: Began a Phase III trial in 990 patients, with partner Marion Merrell Dow to test f

Alteon Inc. (ALTN), Ramsey, N.J. Product: Pimagedine inhibitor of the formation of advanced glycosylation end products Indication: Kidney damage in Type II diabetes Status: Began a Phase III trial in ...